Mannitol as adjunct therapy for childhood cerebral malaria in Uganda: A randomized clinical trial
2007

Mannitol for Childhood Cerebral Malaria

Sample size: 156 publication Evidence: low

Author Information

Author(s): Namutangula Beatrice, Ndeezi Grace, Byarugaba Justus S, Tumwine James K

Primary Institution: Makerere University Medical School

Hypothesis

Does intravenous mannitol improve clinical outcomes in children with cerebral malaria?

Conclusion

Mannitol had no significant impact on the clinical outcome of cerebral malaria.

Supporting Evidence

  • Time to regain consciousness was similar between mannitol and placebo groups.
  • Mortality rates were not significantly different between the two groups.
  • No adverse effects were observed after administration of mannitol.

Takeaway

The study tested if a medicine called mannitol could help kids with a serious brain infection called cerebral malaria, but it didn't make a difference.

Methodology

A randomized double-blind placebo-controlled trial was conducted with 156 children aged 6 to 60 months with cerebral malaria, comparing mannitol to placebo in addition to intravenous quinine.

Potential Biases

Potential bias due to imprecise diagnosis of cerebral malaria.

Limitations

The study may not have been powered to detect differences in mortality, and intracranial pressure was not measured.

Participant Demographics

Children aged 6 to 60 months with cerebral malaria.

Statistical Information

Confidence Interval

CI 0.5–2.7

Digital Object Identifier (DOI)

10.1186/1475-2875-6-138

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication